The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma

Creative Commons License

Pinato D. J., Sharma R., Allara E., Yen C., Arizumi T., Kubota K., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.66, sa.2, ss.338-346, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 66 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.jhep.2016.09.008
  • Dergi Adı: JOURNAL OF HEPATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.338-346
  • Anahtar Kelimeler: Prognosis, Carcinoma, Hepatocellular, Liver failure, ALBI, Albumins, Bilirubin, Retrospective studies, Biomarkers
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background & Aims: Overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI grade is a recently described index of liver dysfunction in hepatocellular carcinoma, based solely on albumin and bilirubin levels. Whilst accurate, this score lacks cross validation, especially in intermediate stage HCC, where OS is highly heterogeneous.